Treating smokers in the health care setting

New England Journal of Medicine

Volumn 365, Issue 13, 2011, Pages 1222-1231

  Fiore, Michael C ^a   Baker, Timothy B ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; VARENICLINE; BENZAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR STIMULATING AGENT; DOPAMINE UPTAKE INHIBITOR; QUINOXALINE DERIVATIVE;

ADVERSE OUTCOME; ATTITUDE TO HEALTH; BRONCHITIS; COUNSELING; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; EVIDENCE BASED PRACTICE; HEALTH CARE ACCESS; HEALTH CARE PRACTICE; HEALTH CARE UTILIZATION; HUMAN; MEDICAL HISTORY; MORNING DOSAGE; MOTIVATION; NICOTINE REPLACEMENT THERAPY; OBESITY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING; SMOKING CESSATION; SMOKING HABIT; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT PLANNING; WEIGHT GAIN; DOCTOR PATIENT RELATION; EVIDENCE BASED MEDICINE; FEMALE; METHODOLOGY; MIDDLE AGED; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; UNITED STATES;

BENZAZEPINES; BUPROPION; CHOLINERGIC AGENTS; COUNSELING; DOPAMINE UPTAKE INHIBITORS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MIDDLE AGED; MOTIVATION; NICOTINE; PATIENT COMPLIANCE; PHYSICIAN-PATIENT RELATIONS; PRACTICE GUIDELINES AS TOPIC; QUINOXALINES; SMOKING; SMOKING CESSATION; UNITED STATES;

EID: 80053350924     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp1101512     Document Type: Review

References (50)

1. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. Health, United States, 2009-2010. (http://www.cdc.gov/nchs/data/hus/hus09.pdf.)
2. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Rockville, MD: Department of Health and Human Services, U.S. Public Health Service, 2008.
3. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey 2007-2008. (http://www.cdc.gov/nchs/nhanes.htm.)
4. Godtfredsen NS, Vestbo J, Osler M, Prescott E. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax 2002;57:967-72. (Pubitemid 35316276)
5. Smoking-attributable mortality, years of potential life lost, and productivity losses - United States, 2000-2004. MMWR Morb Mortal Wkly Rep 2008;57:1226-8.
6. Fiel SB. Chronic obstructive pulmonary disease: mortality and mortality reduction. Drugs 1996;52:Suppl 2:55-60.
7. Toll of tobacco in the United States of America. Washington, DC: Campaign for Tobacco-Free Kids, 2010. (http://www.tobaccofreekids.org/research/ factsheets/pdf/0072.pdf.)
8. Annual smoking-attributable mortality, years of potential life lost, and economic costs - United States, 1995-1999. MMWR Morb Mortal Wkly Rep 2002;51:300-3.
9. Russell MA, Feyerabend C, Cole PV. Plasma nicotine levels after cigarette smoking and chewing nicotine gum. BMJ 1976;1:1043-6.
10. Benowitz NL. Nicotine addiction. N Engl J Med 2010;362:2295-303.
11. Baker TB, Piper ME, McCarthy DE, Majeskie MR, Fiore MC. Addiction motivation reformulated: an affective processing model of negative reinforcement. Psychol Rev 2004;111:33-51. (Pubitemid 38157073)
12. Lessov-Schlaggar CN, Pergadia ML, Khroyan TV, Swan GE. Genetics of nicotine dependence and pharmacotherapy. Biochem Pharmacol 2008;75:178-95. (Pubitemid 350235400)
13. Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Use of smoking-cessation treatments in the United States. Am J Prev Med 2008;34:102-11.
14. National Cancer Institute. Cancer trends progress report - 2009/2010 update. (http://progressreport.cancer.gov.)
15. Novotny TE, Cohen JC, Yurekli A, Sweanor DT, De Beyer J. Smoking cessation and nicotine replacement therapies. In: Jha P, Chaloupka F, eds. Tobacco control in developing countries. New York: Oxford University Press, 2000:287-310.
16. Shiffman S, Sweeney CT, Ferguson SG, Sembower MA, Gitchell JG. Relationship between adherence to daily nicotine patch use and treatment efficacy: secondary analysis of a 10-week randomized, double-blind, placebo-controlled clinical trial simulating over-the-counter use in adult smokers. Clin Ther 2008;30:1852-8.
17. Smith SS, McCarthy DE, Japuntich SJ, et al. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med 2009; 169:2148-55.
18. Physician and other health-care professional counseling of smokers to quit - United States, 1991. MMWR Morb Mortal Wkly Rep 1993;42:854-7.
19. Fiore MC, Jorenby DE, Schensky AE, Smith SS, Bauer RR, Baker TB. Smoking status as the new vital sign: effect on assessment and intervention in patients who smoke. Mayo Clin Proc 1995;70:209-13.
20. Hettema J, Steele J, Miller WR. Motivational interviewing. Annu Rev Clin Psychol 2005;1:91-111. (Pubitemid 43843947)
21. Lai DT, Cahill K, Qin Y, Tang JL. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev 2010; 1:CD006936.
22. Carpenter MJ, Hughes JR, Solomon LJ, Callas PW. Both smoking reduction with nicotine replacement therapy and motivational advice increase future cessation among smokers unmotivated to quit. J Consult Clin Psychol 2004;72:371-81. (Pubitemid 38679635)
23. Wennike P, Danielsson T, Landfeldt B, Westin A, Tonnesen P. Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction 2003;98:1395-402. (Pubitemid 37297246)
24. Hughes JR, Carpenter MJ. The feasibility of smoking reduction: an update. Addiction 2005;100:1074-89. (Pubitemid 41113601)
25. Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ 2009;338:b1024.
26. Chan SS, Leung DY, Abdullah AS, Wong VT, Hedley AJ, Lam TH. A randomized controlled trial of a smoking reduction plus nicotine replacement therapy intervention for smokers not willing to quit smoking. Addiction 2011;106:1155-63.
27. Lichtenstein E, Hollis J. Patient referral to a smoking cessation program: who follows through? J Fam Pract 1992;34:739-44. (Pubitemid 23031955)
28. Fiore MC, McCarthy DE, Jackson TC, et al. Integrating smoking cessation treatment into primary care: an effectiveness study. Prev Med 2004;38:412-20. (Pubitemid 38327013)
29. Peters EN, Hughes JR. The day-to-day process of stopping or reducing smoking: a prospective study of self-changers. Nicotine Tob Res 2009;11:1083-92. [Erratum, Nicotine Tobacco Res 2010;12:77.]
30. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005; 2:CD001292.
31. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008;1:CD000146.
32. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007;1:CD006103.
33. Piper ME, Smith SS, Schlam TR, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry 2009;66: 1253-62. [Erratum, Arch Gen Psychiatry 2010;67:77.]
34. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47-55.
35. Rose JE. New findings on nicotine addiction and treatment. Nebr Symp Motiv 2009;55:131-41.
36. Lindson N, Aveyard P. An updated meta-analysis of nicotine preloading for smoking cessation: investigating mediators of the effect. Psychopharmacology (Berl) 2011;214:579-92.
37. West R, Zatonski W, Cedzynska M, et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 2011; 365:1193-200.
38. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010; 121:221-9.
39. Mills EJ, Ping W, Lockhart I, Kumanan W, Ebbert JO. Adverse event associated with nicotine replacement therapy (NRT) for smoking cessation: a systematic review and meta-analysis of one hundred and twenty studies involving 177,390 adults. Tobacco Induced Diseases 2010; 8:8.
40. Hjalmarson A, Boëthius G. The effectiveness of brief advice and extended smoking cessation counseling programs when implemented routinely in hospitals. Prev Med 2007;45:202-7. (Pubitemid 47348088)
41. Vogt F, Hall S, Marteau TM. Understanding why smokers do not want to use nicotine dependence medications to stop smoking: qualitative and quantitative studies. Nicotine Tob Res 2008;10:1405-13.
42. Japuntich SJ, Piper ME, Leventhal AM, Bolt DM, Baker TB. The effect of five smoking cessation pharmacotherapies on smoking cessation milestones. J Consult Clin Psychol 2011;79:34-42.
43. Curry SJ, Grothaus LC, McAfee T, Pabiniak C. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. N Engl J Med 1998;339:673-9. (Pubitemid 28402093)
44. Medicare.gov. Smoking cessation. (http://www.medicare.gov/navigation/ manage-your-health/preventive-services/ smoking-cessation.aspx?AspxAutoDetect CookieSupport=1.)
45. Lindholm C, Adsit R, Bain P, et al. A demonstration project for using the electronic health record to identify and treat tobacco users. WMJ 2010;109:335-40.
46. Kobinsky KH, Redmond LA, Smith SS, Yepassis-Zembrou PL, Fiore MC. The Wisconsin Tobacco Quit Line's Fax to Quit program: participant satisfaction and effectiveness. WMJ 2010;109:79-84.
47. Hughes JR. How confident should we be that smoking cessation treatments work? Addiction 2009;104:1637-40.
48. Kinnunen T, Korhonen T, Garvey AJ. Role of nicotine gum and pretreatment depressive symptoms in smoking cessation: twelve-month results of a randomized placebo controlled trial. Int J Psychiatry Med 2008;38:373-89.
49. Baker TB, Piper ME, McCarthy DE, et al. Time to first cigarette in the morning as an index of ability to quit smoking: implications for nicotine dependence. Nicotine Tob Res 2007;9:Suppl 4:S555-S570.
50. Loh W-Y, Piper ME, Schlam TR, et al. Should all smokers use combination smoking cessation pharmacotherapy? Using novel analytic methods to detect differential treatment effects over 8 weeks of pharmacotherapy. Nicotine Tob Res (in press).